<p>In the early 1860s three Swedes, Nils Wilhelm Mitander,Julius Ramsay and Gustaf Wittenström, were engaged by theBritish to build and run charcoal-based ironworks in India.These works, the Burwai Iron Works of the British Government inthe case of Mitander and the privately owned Kumaon Iron Worksin the case of Ramsay and Wittenström, were both to bebased on the most modern European technology. The projects werepioneering in Indian ironmaking. The ambitions were high andstakes big, but after only a few years the projects were closedand the Swedes returned home.<i>Landscapes of Technology Transfer</i>presents a detailedstudy of the Kumaon and Burwai Iron Works, from their firstconception to their final closure. The investigation isbasically empirical and a fundamental question is: Why were theworks never brought into full and continuous production?</p><p>The ironworks projects should be considered as processes oftechnology transfer rather than fully fledged and completedtransfers. In spite of this lack of success, or maybe becauseof it, the history of the ironworks and the Swedes also forms afruitful case to put other questions of wide relevance. Itexposes workings and effects of colonialism and offers anexplanation of the late development of India's iron and steelindustry and analyses of the complex totality forming theprerequisites for a successful transfer of technology. The longtraditions of bloomery ironmaking in India and ismarginalisation is also discussed.</p><p><i>Landscapes of Technology Transfer</i>is a comprehensiveempirical study. From a local and individual perspective ittraces lines of connection across boundaries of time andgeography. The historical landscapes of technology transfer aredescribed in their cultural, social, economic and politicaldimensions and the thesis underlines the importance of a closeacquaintance with local settings and conditions, where historyis manifested in a physical presence. The remains of theironworks and theirlocal landscapes in present-day India areused as a central source for writing their histories. There isalso a strong emphasis on the use of photographs and drawingsas sources.</p><p>The outcome of the projects was the result of the interplaybetween the local and the global, between a diversity ofconcrete factors influencing the construction of the works andtheir running and their colonial character. The studyemphasises the importance of technological systems andnetworks, both on a micro and a macro level. On a local leveldemanding logistics, a sometimes adverse climate, theprocurement of charcoal and iron ore in sufficient quantitiesand the build up of knowledge of ironmaking posed serious butnot insurmountable difficulties. Most obstacles were overcomealready during the first few years of the 1860s, the period ofthe Swedes, but to put the works into full and continuousproduction would have needed perseverance and purposefulefforts to support and protect the iron production, at leastduring an initial period. In the end the position of India as acolonial dependency, subjected to the primacy of Britishinterests, set the limits of the projects.</p><p><b>Key words:</b>History of technology, industrial heritagestudies, industrial archaeology, technology transfer,diffusion, technological systems, landscapes of technology,iron and steel, charcoal iron, direct and indirect ironmaking,bloomeries, 19th century, industrial history,industrialisation, de-industrialisation, underdevelopment,colonialism, India, Sweden, Great Britain, global history,annales.</p>

Die aktuelle Ausgabe des Newsletter für Freunde, Absolventen und Ehemalige der Technischen Universität Chemnitz.

In dem vom Bundesministerium für Bildung und Forschung über den Projektträger VDI/VDE-IT geförderten Vorhaben "Wirksamkeitsbeurteilung von Transferformen zwischen Wissenschaft und Wirtschaft für die Branchen Produktionstechnik, Umwelttechnologie und Materialforschung" wurden unterschiedliche Formen und Wege des Wissens- und Technologietransfers zwischen Wissenschaft und Wirtschaft analysiert und beschrieben, um Erfolgsmuster für deren Zusammenarbeit aufzuspüren.

Texte remanié de : Thèse de 3e cycle :? : Université de Munich (RFA) : 2003. / Bibliogr. p. 155-163. Notes bibliogr.

das Jahrbuch der Technischen Universität Chemnitz 2014/2015 / the yearbook of Technische Universität Chemnitz 2014/2015

The Convention on Biological Diversity (CBD) significantly enhanced the scope and potential effectiveness of the international legal regime for the conservation of biological diversity world wide together with the sustainable use of its components. It goes beyond the conservation of biological conservation per se and comprehends such diverse issues as sustainable use of biological resources, access to genetic resources, the sharing of benefits derived from the use of genetic material and technology, including biotechnology. The CBD has three objectives, which are the conservation of biological diversity, secondly the sustainable use of its components and thirdly the fair and equitable sharing of benefits arising out of the utilisation of genetic resources. The third objective includes the sharing of benefits by means of appropriate access to genetic resources and by appropriate transfer of relevant technologies, taking into account all rights over such resources and technologies as well as appropriate funding. As part of the process of achieving these goals, the CBD establishes a new international framework for access to genetic resources and the sharing of benefits from their use. In addition to its conservation measures, the CBD is also an economic treaty in the sense that it develops and regulates the ongoing exchange of genetic resources and, in particular, the emerging trade in biotechnology. During the negotiations of the CBD the concept of the trade in biotechnology dominated much of the discussions surrounding the Convention. This was the cause of deep differences between the technologically rich north and the biodiversity rich south. It was and still is apparent that developed countries, or corporate companies in these countries, exploit natural recourses only found in developing countries, without sharing the resulting proceeds. It is shown that uneven distribution of natural, technological and economic resources occur in relationships between the northern hemisphere and its southern counterpart. It is a well-known fact that the northern hemisphere is financially and technologically superior to its southern counterpart. Intellectual property rights ("IPR"), with specific reference to patent law, enables developed countries andlor companies in those countries to exploit this economic discrepancy. Developed countries accordingly acquire biological recourses and exploit them with resulting benefits thereby circumventing the sharing of such benefits through IPR systems. Benefits are thereby withheld from developing countries that provide such genetic recourses. The author will mainly focus on the question that arises as to how the CBD addresses benefit sharing in the light of the differences between the northern developed- and southern developing countries. South Africa will be studied as an example of a developing country that incorporated the provisions of the CBD in its national legislation as it promulgated the National Environmental Management: Biodiversity Act (BDA), which embodies the guidelines and principles for bioprospecting and benefit sharing, captured in the CBD and the Cartagena Protocol. The provisions contained in the BDA will be used as a practical example of the application of the CBD in the municipal law of developing countries. / Thesis (LL.M. (Import and Export Law))--North-West University, Potchefstroom Campus, 2007.

Statement of the issue: Facing large HIV-infected populations, Sub-Saharan African countries are producing antiretroviral (ARV) drugs under provisions of the World Trade Organization’s Agreement on the Trade-Related Aspects of Intellectual Property (TRIPS). Article 7 states that the protection of intellectual property should increase technology transfer to developing countries. This clause and the debate over domestic manufacturers’ ability to provide low-cost ARVs need examination. Methods: Case studies from ARV manufacturing initiatives in Tanzania and South Africa analyzed conditions affecting two outcomes: the type of technology transfer arrangement entered (voluntary license or imitation) and the affordability of ARVs. Data were collected and analyzed from documents, key-informant interviews, and observation. Chi-squared and phi correlation statistics were then conducted across developing countries to test the association of voluntary ARV licensure with TRIPS-compliant patents and domestic firm ownership (state or private). Results: Tanzania’s weak patent system and poorly-financed, partially state-owned firm dissuaded industry investment, but attracted a non-government organization to transfer technology through imitation. Donor-financed ARV tenders, however, restrict competition to international quality-accredited products not produced by the firm. Without large volumes and manufacturing capacity, it cannot achieve economies of scale to reduce prices below imported ARVs. In South Africa, civil society challenged the strong patent system and poor government commitment that inhibited an ARV rollout. This and a well-financed, publicly-traded firm leveraged voluntary licenses. With international quality approval, the firm increased first-line ARV affordability; however, limited domestic competition keeps treatment prices above those of neighbouring countries. A multi-country analysis found 321 generic ARV manufacturing initiatives in 86 firms across 25 developing countries. Voluntary ARV licenses had a strong positive association with TRIPS-patent compliance (ф=.56, p<.0001) and a weak negative association with state-ownership (ф=.19, p<.0001). Firms in South Africa and India were granted 77% of licenses and accounted for most quality accredited generic ARVs. Conclusion: Despite positive association, technology transfer does not readily result from patent protection, particularly to state-owned firms. Developing countries must enact policies to enable affordable ARVs; yet, they must be cautious using local production to increase ARV access, as most initiatives cannot compete with high-volume generic manufacturers.

Collaboration between academic and corporate entities has increased in recent years. On many occasions Government actors (e.g. federal laboratories) will participate in these collaborations, especially when advanced technologies are involved. The following inquiry considers the degree to which the federal entities add (scientific) value to University-Industry partnerships and how this value is spatially mediated. Quantifying degrees of the value that Government actors induce across the spectrum of University-Industry collaborative arrangements is useful for identifying scales at which intervention by federal agents is more effective and/or justified. It is anticipated that the value-added by federal agents in University-Industry collaboration is not spatially uniform but will exhibit greater profitability across specific scales of interaction. Comparing these against actual scales of interaction provides room for discussion on whether Government actors engage Universities and Industry at scales that optimize the value they introduce to these partnerships.

The Convention on Biological Diversity (CBD) significantly enhanced the scope and potential effectiveness of the international legal regime for the conservation of biological diversity world wide together with the sustainable use of its components. It goes beyond the conservation of biological conservation per se and comprehends such diverse issues as sustainable use of biological resources, access to genetic resources, the sharing of benefits derived from the use of genetic material and technology, including biotechnology. The CBD has three objectives, which are the conservation of biological diversity, secondly the sustainable use of its components and thirdly the fair and equitable sharing of benefits arising out of the utilisation of genetic resources. The third objective includes the sharing of benefits by means of appropriate access to genetic resources and by appropriate transfer of relevant technologies, taking into account all rights over such resources and technologies as well as appropriate funding. As part of the process of achieving these goals, the CBD establishes a new international framework for access to genetic resources and the sharing of benefits from their use. In addition to its conservation measures, the CBD is also an economic treaty in the sense that it develops and regulates the ongoing exchange of genetic resources and, in particular, the emerging trade in biotechnology. During the negotiations of the CBD the concept of the trade in biotechnology dominated much of the discussions surrounding the Convention. This was the cause of deep differences between the technologically rich north and the biodiversity rich south. It was and still is apparent that developed countries, or corporate companies in these countries, exploit natural recourses only found in developing countries, without sharing the resulting proceeds. It is shown that uneven distribution of natural, technological and economic resources occur in relationships between the northern hemisphere and its southern counterpart. It is a well-known fact that the northern hemisphere is financially and technologically superior to its southern counterpart. Intellectual property rights ("IPR"), with specific reference to patent law, enables developed countries andlor companies in those countries to exploit this economic discrepancy. Developed countries accordingly acquire biological recourses and exploit them with resulting benefits thereby circumventing the sharing of such benefits through IPR systems. Benefits are thereby withheld from developing countries that provide such genetic recourses. The author will mainly focus on the question that arises as to how the CBD addresses benefit sharing in the light of the differences between the northern developed- and southern developing countries. South Africa will be studied as an example of a developing country that incorporated the provisions of the CBD in its national legislation as it promulgated the National Environmental Management: Biodiversity Act (BDA), which embodies the guidelines and principles for bioprospecting and benefit sharing, captured in the CBD and the Cartagena Protocol. The provisions contained in the BDA will be used as a practical example of the application of the CBD in the municipal law of developing countries. / Thesis (LL.M. (Import and Export Law))--North-West University, Potchefstroom Campus, 2007.

Statement of the issue: Facing large HIV-infected populations, Sub-Saharan African countries are producing antiretroviral (ARV) drugs under provisions of the World Trade Organization’s Agreement on the Trade-Related Aspects of Intellectual Property (TRIPS). Article 7 states that the protection of intellectual property should increase technology transfer to developing countries. This clause and the debate over domestic manufacturers’ ability to provide low-cost ARVs need examination. Methods: Case studies from ARV manufacturing initiatives in Tanzania and South Africa analyzed conditions affecting two outcomes: the type of technology transfer arrangement entered (voluntary license or imitation) and the affordability of ARVs. Data were collected and analyzed from documents, key-informant interviews, and observation. Chi-squared and phi correlation statistics were then conducted across developing countries to test the association of voluntary ARV licensure with TRIPS-compliant patents and domestic firm ownership (state or private). Results: Tanzania’s weak patent system and poorly-financed, partially state-owned firm dissuaded industry investment, but attracted a non-government organization to transfer technology through imitation. Donor-financed ARV tenders, however, restrict competition to international quality-accredited products not produced by the firm. Without large volumes and manufacturing capacity, it cannot achieve economies of scale to reduce prices below imported ARVs. In South Africa, civil society challenged the strong patent system and poor government commitment that inhibited an ARV rollout. This and a well-financed, publicly-traded firm leveraged voluntary licenses. With international quality approval, the firm increased first-line ARV affordability; however, limited domestic competition keeps treatment prices above those of neighbouring countries. A multi-country analysis found 321 generic ARV manufacturing initiatives in 86 firms across 25 developing countries. Voluntary ARV licenses had a strong positive association with TRIPS-patent compliance (ф=.56, p<.0001) and a weak negative association with state-ownership (ф=.19, p<.0001). Firms in South Africa and India were granted 77% of licenses and accounted for most quality accredited generic ARVs. Conclusion: Despite positive association, technology transfer does not readily result from patent protection, particularly to state-owned firms. Developing countries must enact policies to enable affordable ARVs; yet, they must be cautious using local production to increase ARV access, as most initiatives cannot compete with high-volume generic manufacturers.